- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
DexCom Inc (DXCM)
DexCom Inc stock price live, this page displays NASDAQ DXCM stock exchange data. View the DXCM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the DexCom Inc real time stock price chart below.
What Is the DexCom Inc Stock Price Today?
The DexCom Inc stock price today is 58.22.
What Is the Stock Symbol for DexCom Inc?
The stock symbol for DexCom Inc is ""DXCM.""
What Stock Exchange Does DexCom Inc Trade On?
DexCom Inc is listed and trades on the NASDAQ stock exchange.
Is DexCom Inc a Good Stock to Buy?
Determining whether DexCom Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DXCM quote. (ISIN: US2521311074)
What Is the DexCom Inc Stock Price Today?
The DexCom Inc stock price today is 58.22.
What Is the Stock Symbol for DexCom Inc?
The stock symbol for DexCom Inc is ""DXCM.""
What Stock Exchange Does DexCom Inc Trade On?
DexCom Inc is listed and trades on the NASDAQ stock exchange.
Is DexCom Inc a Good Stock to Buy?
Determining whether DexCom Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DXCM quote. (ISIN: US2521311074)
Fair Value
An estimate of a DexCom's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
56.45
60.36
52 wk Range
56.44
93.25
DXCM Scorecard
Full Analysis
Management has been aggressively buying back shares
Unusual trading volume
1/2
Fair Value
An estimate of a DexCom's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
56.4560.36
52 wk Range
56.4493.25
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DXCM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a DexCom's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
88.44
Upside
+51.91%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
- DexCom receives Investment Bank Analyst Rating Update
- Investing.com
Pro - DexCom receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- DexCom stock hits 52-week low at 57.5 USD
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
DexCom Inc Company Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
DexCom Inc SWOT Analysis
CGM Market Leade | Explore DexCom's dominant position in continuous glucose monitoring technology, driving innovation and expanding market reach in diabetes management |
Financial Resilience | Delve into DexCom's robust financial performance, with $4.15 billion in trailing twelve-month revenue and a strong gross margin of 59.43% |
Growth Catalysts | Uncover DexCom's strategic expansion into Type 2 diabetes market and international growth potential, positioning the company for sustained success |
Analyst Outlook | Average price target of $99, with analysts projecting potential outperformance and anticipating DexCom to exceed its conservative 2025 revenue guidance |
DexCom Inc Earnings Call Summary for Q3/2025
- DexCom exceeded Q3 2025 expectations with EPS of $0.61 (7.02% above forecast) and revenue of $1.21 billion (2.54% above forecast), while maintaining stable stock price post-earnings.
- Revenue grew 22% year-over-year with strong performance in both U.S. ($852M, +21%) and international markets ($357.4M, +22%), resulting in record-high quarterly earnings.
- The company raised its 2025 revenue guidance to $4.63-$4.65 billion, projecting 15% growth and anticipating record new patient starts in 2026, particularly in the Type 2 diabetes market.
- DexCom launched new products including Dexcom Smart Basal and a 15-day sensor system, while maintaining a strong financial position with over $3.3 billion in cash and cash equivalents.
- Jake Leach, President and Interim CEO, emphasized the company's customer-centric approach, while CFO Jereme Sylvain highlighted ongoing operational improvements to deliver margin growth.
Last Updated: 30/10/2025, 23:08
Read Full TranscriptCompare DXCM to Peers and Sector
Metrics to compare | DXCM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDXCMPeersSector | |
|---|---|---|---|---|
P/E Ratio | 46.8x | −10.4x | −0.7x | |
PEG Ratio | −3.50 | −0.30 | 0.00 | |
Price/Book | 10.4x | 3.9x | 2.6x | |
Price / LTM Sales | 6.2x | 6.3x | 3.4x | |
Upside (Analyst Target) | 71.8% | 51.8% | 39.3% | |
Fair Value Upside | Unlock | 4.9% | 5.7% | Unlock |
Analyst Ratings
24 Buy
4 Hold
0 Sell
Ratings:
28 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 88.44
(+51.91% Upside)
Earnings
Latest Release
Oct 30, 2025
EPS / Forecast
0.61 / 0.57
Revenue / Forecast
1.21B / 1.18B
People Also Watch
FAQ
What Stock Exchange Does DexCom Trade On?
DexCom is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for DexCom?
The stock symbol for DexCom is "DXCM."
What Is the DexCom Market Cap?
As of today, DexCom market cap is 22.71B.
What Is DexCom's Earnings Per Share (TTM)?
The DexCom EPS (TTM) is 1.84.
When Is the Next DexCom Earnings Date?
DexCom will release its next earnings report on 04 Feb 2026.
From a Technical Analysis Perspective, Is DXCM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has DexCom Stock Split?
DexCom has split 1 times.
How Many Employees Does DexCom Have?
DexCom has 10250 employees.
What is the current trading status of DexCom (DXCM)?
As of 01 Nov 2025, DexCom (DXCM) is trading at a price of 58.22, with a previous close of 68.20. The stock has fluctuated within a day range of 56.45 to 60.36, while its 52-week range spans from 56.44 to 93.25.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.